Today, the Treas. & CFO of Enanta Pharmaceuticals, Paul Mellett, exercised options of Enanta Pharmaceuticals (NASDAQ: ENTA) for $13.78K. The options were close to expired and Paul Mellett retained stocks.
Following Paul Mellett’s last ENTA Buy transaction on April 12, 2017, the stock climbed by 84.7%. Following this transaction Paul Mellett’s holding in the company was increased by 9.47% to a total of $9.18 million.
See today’s analyst top recommended stocks >>
Based on Enanta Pharmaceuticals’ latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $44.05 million and quarterly net profit of $12.56 million. In comparison, last year the company earned revenue of $8.96 million and had a GAAP net loss of $5.39 million. ENTA’s market cap is $2.2B and the company has a P/E ratio of 43.58. Currently, Enanta Pharmaceuticals has an average volume of 368.1K.
10 different firms, including Barclays and Credit Suisse, currently also have a Buy rating on the stock. One of the top 25 analysts, according to TipRanks.com, recently recommended Buy ENTA with a $133 price target. Based on 3 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $116.00, reflecting a -0.6% downside.
Paul Mellett’s trades have generated a 75.3% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Enanta Pharmaceuticals, Inc. engages in the research and development of small molecule drugs for the treatment of viral infections and liver diseases. It offers the two protease inhibitors Maviret and the Viekira Pak for the treatment of chronic hepatitis C virus.
